Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Economic burden of cancer in the United States: estimates, projections, and future research.

Yabroff KR, Lund J, Kepka D, Mariotto A.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14. doi: 10.1158/1055-9965.EPI-11-0650.

2.

American Society of Clinical Oncology guidance statement: the cost of cancer care.

Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, Ubel PA, Schnipper LE; American Society of Clinical Oncology.

J Clin Oncol. 2009 Aug 10;27(23):3868-74. doi: 10.1200/JCO.2009.23.1183. Epub 2009 Jul 6.

3.

The Medical Expenditure Panel Survey (MEPS) experiences with cancer survivorship supplement.

Yabroff KR, Dowling E, Rodriguez J, Ekwueme DU, Meissner H, Soni A, Lerro C, Willis G, Forsythe LP, Borowski L, Virgo KS.

J Cancer Surviv. 2012 Dec;6(4):407-19. doi: 10.1007/s11764-012-0221-2. Epub 2012 Jul 19.

PMID:
23011572
4.

Projections of the cost of cancer care in the United States: 2010-2020.

Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML.

J Natl Cancer Inst. 2011 Jan 19;103(2):117-28. doi: 10.1093/jnci/djq495. Epub 2011 Jan 12. Erratum in: J Natl Cancer Inst. 2011 Apr 20;103(8):699.

5.

The high cost of cancer drugs and what we can do about it.

Siddiqui M, Rajkumar SV.

Mayo Clin Proc. 2012 Oct;87(10):935-43. doi: 10.1016/j.mayocp.2012.07.007. No abstract available.

6.

Projections of the costs associated with colorectal cancer care in the United States, 2000-2020.

Yabroff KR, Mariotto AB, Feuer E, Brown ML.

Health Econ. 2008 Aug;17(8):947-59.

PMID:
17910108
7.

Economic burden of cancer across the European Union: a population-based cost analysis.

Luengo-Fernandez R, Leal J, Gray A, Sullivan R.

Lancet Oncol. 2013 Nov;14(12):1165-74. doi: 10.1016/S1470-2045(13)70442-X. Epub 2013 Oct 14.

PMID:
24131614
8.

Economic burden of cancer survivorship among adults in the United States.

Guy GP Jr, Ekwueme DU, Yabroff KR, Dowling EC, Li C, Rodriguez JL, de Moor JS, Virgo KS.

J Clin Oncol. 2013 Oct 20;31(30):3749-57. doi: 10.1200/JCO.2013.49.1241. Epub 2013 Sep 16.

9.

Can treatment costs be tamed?

Malakoff D.

Science. 2011 Mar 25;331(6024):1545-7. doi: 10.1126/science.331.6024.1545. No abstract available.

PMID:
21436438
10.

Realigning incentives for developing and pricing new anticancer treatments.

Howard DH.

JAMA. 2011 Jun 8;305(22):2347-8. doi: 10.1001/jama.2011.793. No abstract available.

PMID:
21642689
11.

Medical costs and productivity losses of cancer survivors--United States, 2008-2011.

Ekwueme DU, Yabroff KR, Guy GP Jr, Banegas MP, de Moor JS, Li C, Han X, Zheng Z, Soni A, Davidoff A, Rechis R, Virgo KS; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2014 Jun 13;63(23):505-10.

12.

Cost of disorders of the brain in Europe 2010.

Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group.

Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Erratum in: Eur Neuropsychopharmacol. 2012 Mar;22(3):237-8. den Bergh, Peter Van [corrected to Van den Bergh, Peter].

PMID:
21924589
13.

Proposal for the breakdown of increased cancer healthcare cost and its improvement.

Koinuma N.

Jpn J Clin Oncol. 2013 Apr;43(4):351-6. doi: 10.1093/jjco/hyt015. Epub 2013 Feb 18. Review.

14.

The economic burden of skin disease in the United States.

Dehkharghani S, Bible J, Chen JG, Feldman SR, Fleischer AB Jr.

J Am Acad Dermatol. 2003 Apr;48(4):592-9.

PMID:
12664024
15.

How much is the life of a cancer patient worth? A pharmaco-economic perspective.

Simoens S, Dooms M.

J Clin Pharm Ther. 2011 Jun;36(3):249-56. doi: 10.1111/j.1365-2710.2010.01181.x. Epub 2010 Aug 24. Review.

PMID:
21545607
16.

The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006.

Ekwueme DU, Guy GP Jr, Li C, Rim SH, Parelkar P, Chen SC.

J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S133-43. doi: 10.1016/j.jaad.2011.04.036.

17.

A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK.

Smith DH, Adams JR, Johnston SR, Gordon A, Drummond MF, Bennett CL.

Ann Oncol. 2002 Oct;13(10):1590-7.

18.

Role of clinical pathways in health care provision: Focus on cancer treatment.

Kreys ED, Koeller JM.

Am J Health Syst Pharm. 2013 Jun 15;70(12):1081-5. doi: 10.2146/ajhp120235. No abstract available.

PMID:
23719888
19.

Outpatient cancer drug costs: changes, drivers, and the future.

Halbert RJ, Zaher C, Wade S, Malin J, Lawless GD, Dubois RW.

Cancer. 2002 Feb 15;94(4):1142-50.

20.

Economic burden of adverse events in patients with metastatic renal cell carcinoma.

Hagiwara M, Borker R, Oster G.

Clin Ther. 2013 Dec;35(12):1955-1963.e2. doi: 10.1016/j.clinthera.2013.10.010. Epub 2013 Nov 28.

PMID:
24290735
Items per page

Supplemental Content

Write to the Help Desk